Skip to main
  1. Stocks
  2. Monte Rosa Therapeutics
  3. Forecast
GLUE

GLUE Stock Forecast & Price Target

GLUE Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Monte Rosa Therapeutics is supported by a differentiated QuEEN platform that has already generated clinical proof-of-concept across three distinct molecular glue degraders, reducing target-risk and strengthening confidence in repeatable discovery. MRT-8102 showed deep human pharmacology, including an 85% median hsCRP reduction and no AE-related discontinuations at 5mg, while MRT-2359 produced PSA50 responses in all five retrospectively identified AR-mutant mCRPC patients with radiographic shrinkage, and MRT-6160 is advancing under a Novartis-funded Phase 2 with a $50M milestone and retained economics. The company also appears financially well-positioned, with about $626 million in cash at June 30, 2026 and guidance to fund operations into 2029, allowing multiple near-term catalysts to test the platform’s clinical and commercial value.

Bears say

Monte Rosa Therapeutics is constrained by an early-stage profile with no product revenue, leaving value heavily dependent on collaboration funding, disciplined spending, and successful clinical execution across MRT-8102, MRT-2359, and MRT-6160. The investment case is weakened by clear safety and dosing uncertainty in MRT-8102, where all eight AE-related discontinuations occurred at 20–40mg and four weeks at 5mg in 27 participants does not establish chronic tolerability, while the program also faces a low cardiovascular probability of approval at 15% and a redesign that pushes GFORCE-2 initiation to 1H27. Competitive and translational risk is elevated because only MRT-2359 has any patient signal from a post hoc five-patient subset, Novartis controls key GLUE economics, and the broader platform still must prove repeatable target discovery, selective degradation, and durable clinical benefit.

GLUE has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Monte Rosa Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

GLUE Analyst Forecast & Price Prediction

Get the latest GLUE stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GLUE

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Monte Rosa Therapeutics (GLUE) Forecast

Analysts have given GLUE a Buy based on their latest research and market trends.

According to 7 analysts, GLUE has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Monte Rosa Therapeutics (GLUE)


GLUE Analyst Forecast & Price Prediction

Get the latest GLUE stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GLUE

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover GLUE stock data and trends